In July 2001, Focal Inc was acquired by Genzyme. Focal, Inc. develops, manufactures and commercializes synthetic, absorbable, liquid surgical sealants based on proprietary polymer technology. Focal's family of FOCALSEAL surgical sealant products is being developed for use inside the body to seal leaks resulting from lung, neurological, cardiovascular and gastrointestinal surgery. Focal has developed two primary formulations of its products, FOCALSEAL-L surgical sealant and FOCALSEAL-S surgical sealant, which have absorption times that parallel long-term and short-term synthetic, absorbable polymer sutures, respectively. FOCALSEAL-L is initially being used to seal air leaks following lung surgery. FOCALSEAL-S surgical sealant will initially be used to seal cerebral spinal fluid leaks following neurosurgery. Focal is developing other applications for the liquid formulations of its polymer technology including local drug delivery systems, synthetic coatings for vascular grafts and tissue coatings to prevent post-surgical adhesions.
